Experienced in Acquired Amegakaryocytic Thrombocytopenia

Ju L. Gao

South Renmin Road, 
Chengdu, CN 
Experienced in Acquired Amegakaryocytic Thrombocytopenia
South Renmin Road, 
Chengdu, CN 
OverviewLocationsClinical Research

Overview

Ju Gao practices in Chengdu, China. Gao is rated as an Experienced expert by MediFind in the treatment of Acquired Amegakaryocytic Thrombocytopenia. Their top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Langerhans Cell Histiocytosis, Histiocytosis, Reticulohistiocytoma, and Bone Marrow Aspiration.

Their clinical research consists of co-authoring 102 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Acquired Amegakaryocytic Thrombocytopenia.

Locations

South Renmin Road, Chengdu, 610041, China
Other Locations
20 S, Renmin Road, Chengdu, 610041, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
Enrollment Status: Terminated
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 1/Phase 2

102 Total Publications

Sulbactam-durlobactam combination therapy for carbapenem-resistant Acinetobacter baumannii sepsis with cutaneous involvement in an infant with acute monocytic leukemia: A case report.
Sulbactam-durlobactam combination therapy for carbapenem-resistant Acinetobacter baumannii sepsis with cutaneous involvement in an infant with acute monocytic leukemia: A case report.
Journal: Frontiers in pharmacology
Published: May 23, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Gao's expertise for a condition
ConditionClose
    View All 43 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile